Skip to main content Back to Top
Advertisement

12/3/2019

Promethazine Injection

Products Affected - Description

    • Phenergan injection, Hikma, 50 mg/mL, 1 mL ampule, 25 count, NDC 00641-6083-25
    • Promethazine injection, Hikma, 50 mg/mL, 1 mL ampule, 25 count, NDC 00641-1496-35

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • X-Gen has promethazine injection available.

Available Products

    • Phenergan injection, Hikma, 25 mg/mL, 1 mL ampule, 25 count, NDC 00641-6082-25
    • Phenergan injection, Hikma, 25 mg/mL, 1 mL vial, 25 count, NDC 00641-6084-25
    • Phenergan injection, Hikma, 50 mg/mL, 1 mL vial, 25 count, NDC 00641-6085-25
    • Promethazine injection, Hikma, 25 mg/mL, 1 mL ampule, 25 count, NDC 00641-1495-35
    • Promethazine injection, Hikma, 25 mg/mL, 1 mL vial, 25 count, NDC 00641-0928-25
    • Promethazine injection, Hikma, 50 mg/mL, 1 mL vial, 25 count, NDC 00641-0929-25
    • Promethazine injection, X-Gen, 25 mg/mL, 1 mL ampule, 25 count, NDC 39822-5525-03
    • Promethazine injection, X-Gen, 50 mg/mL, 1 mL ampule, 25 count, NDC 39822-5550-06

Estimated Resupply Dates

    • Hikma has promethazine 50 mg/mL 1 mL ampules on back order and the company estimates a release date of late-December 2019.
    • Hikma has Phenergan 50 mg/mL 1 mL ampules on back order and the company estimates a release date of late-January 2020.

Updated

Updated December 3, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins